Browse SERPINA1

Summary
SymbolSERPINA1
Nameserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
Aliases AAT; A1A; PI1; alpha-1-antitrypsin; A1AT; alpha1AT; protease inhibitor 1 (anti-elastase), alpha-1-antitrypsi ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted. Endoplasmic reticulum. Note=The S and Z allele are not secreted effectively and accumulate intracellularly in the endoplasmic reticulum.; SUBCELLULAR LOCATION: Short peptide from AAT: Secreted, extracellular space, extracellular matrix.
Domain PF00079 Serpin (serine protease inhibitor)
Function

Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin.; FUNCTION: Short peptide from AAT: reversible chymotrypsin inhibitor. It also inhibits elastase, but not trypsin. Its major physiological function is the protection of the lower respiratory tract against proteolytic destruction by human leukocyte elastase (HLE).

> Gene Ontology
 
Biological Process GO:0002526 acute inflammatory response
GO:0002576 platelet degranulation
GO:0006887 exocytosis
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006900 membrane budding
GO:0006901 vesicle coating
GO:0006903 vesicle targeting
GO:0006953 acute-phase response
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0010466 negative regulation of peptidase activity
GO:0010951 negative regulation of endopeptidase activity
GO:0016050 vesicle organization
GO:0045055 regulated exocytosis
GO:0045861 negative regulation of proteolysis
GO:0048193 Golgi vesicle transport
GO:0048199 vesicle targeting, to, from or within Golgi
GO:0048207 vesicle targeting, rough ER to cis-Golgi
GO:0048208 COPII vesicle coating
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0051346 negative regulation of hydrolase activity
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0090114 COPII-coated vesicle budding
Molecular Function GO:0001948 glycoprotein binding
GO:0002020 protease binding
GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0004867 serine-type endopeptidase inhibitor activity
GO:0030414 peptidase inhibitor activity
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005788 endoplasmic reticulum lumen
GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0030133 transport vesicle
GO:0030134 ER to Golgi transport vesicle
GO:0030135 coated vesicle
GO:0030141 secretory granule
GO:0031091 platelet alpha granule
GO:0031093 platelet alpha granule lumen
GO:0031983 vesicle lumen
GO:0033116 endoplasmic reticulum-Golgi intermediate compartment membrane
GO:0034774 secretory granule lumen
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-204005: COPII (Coat Protein 2) Mediated Vesicle Transport
R-HSA-5694530: Cargo concentration in the ER
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-597592: Post-translational protein modification
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolSERPINA1
Nameserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
Aliases AAT; A1A; PI1; alpha-1-antitrypsin; A1AT; alpha1AT; protease inhibitor 1 (anti-elastase), alpha-1-antitrypsi ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SERPINA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SERPINA1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18438953Cervical carcinomaInhibit immunityElevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. Especially SerpinA1 and SerpinA3 were found to be up-regulated in HLA-positive tumours (3.6- and 8.2-fold, respectively), and this was confirmed by real-time PCR and immunohistochemistry. In a group of 117 tumours, high SerpinA1 and SerpinA3 expression in association with normal/partial HLA expression correlated significantly with poor overall survival (p = 0.035 and p = 0.05, respectively). Thus, HLA-positive tumours are characterized by higher expression of genes associated with an inflammatory profile. In addition, expression of the acute phase proteins SerpinA1 and SerpinA3 in HLA-positive tumours is associated with worse prognosis.
Summary
SymbolSERPINA1
Nameserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
Aliases AAT; A1A; PI1; alpha-1-antitrypsin; A1AT; alpha1AT; protease inhibitor 1 (anti-elastase), alpha-1-antitrypsi ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SERPINA1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSERPINA1
Nameserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
Aliases AAT; A1A; PI1; alpha-1-antitrypsin; A1AT; alpha1AT; protease inhibitor 1 (anti-elastase), alpha-1-antitrypsi ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SERPINA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0460.956
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.430.54
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.130.514
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3770.598
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3770.84
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.3350.582
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3960.641
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8070.655
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2280.916
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0690.983
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4670.923
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5940.0584
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SERPINA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277306.8-6.80.32
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275908.5-8.50.32
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSERPINA1
Nameserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
Aliases AAT; A1A; PI1; alpha-1-antitrypsin; A1AT; alpha1AT; protease inhibitor 1 (anti-elastase), alpha-1-antitrypsi ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SERPINA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSERPINA1
Nameserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
Aliases AAT; A1A; PI1; alpha-1-antitrypsin; A1AT; alpha1AT; protease inhibitor 1 (anti-elastase), alpha-1-antitrypsi ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SERPINA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SERPINA1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSERPINA1
Nameserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
Aliases AAT; A1A; PI1; alpha-1-antitrypsin; A1AT; alpha1AT; protease inhibitor 1 (anti-elastase), alpha-1-antitrypsi ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SERPINA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSERPINA1
Nameserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
Aliases AAT; A1A; PI1; alpha-1-antitrypsin; A1AT; alpha1AT; protease inhibitor 1 (anti-elastase), alpha-1-antitrypsi ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SERPINA1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSERPINA1
Nameserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
Aliases AAT; A1A; PI1; alpha-1-antitrypsin; A1AT; alpha1AT; protease inhibitor 1 (anti-elastase), alpha-1-antitrypsi ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SERPINA1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSERPINA1
Nameserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1
Aliases AAT; A1A; PI1; alpha-1-antitrypsin; A1AT; alpha1AT; protease inhibitor 1 (anti-elastase), alpha-1-antitrypsi ......
Chromosomal Location14q32.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SERPINA1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SERPINA1.
ID Name Drug Type Targets #Targets
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB019982-[3,4-Dihydroxy-2-Hydroxymethyl-5-(2-Hydroxy-Nonyl)-Tetrahydro-Furan-2-Yloxy]-6-Hydroxymethyl-Tetra Hydro-Pyran-3,4,5-TriolSmall MoleculeSERPINA11
DB03345Beta-MercaptoethanolSmall MoleculeGLO1, LGALS1, PNPO, SCMH1, SERPINA15
DB05481Recombinant alpha 1-antitrypsinSmall MoleculeSERPINA11
DB05961PPL-100Small MoleculeSERPINA1, SERPINA5, SERPING13
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141